

[Normax ESI \(Extreme Social Impact\) for Stakeholders and Investors](#)

[The EXTREME COST](#) of the COVID pandemic? NEVER AGAIN!

mRNA vaccine technology is a transformative new sector of the biopharmaceutical industry which has revolutionized vaccine development and is helping to end the COVID-19 pandemic.

A brief summary of the expected social impact of Normax...

The purpose of Normax is to help save lives with mRNA vaccines, therapies, health technologies and finance, with our people, partners, providers, investors, stakeholders, customers and communities.

mRNA vaccines and therapies by Normax and Vax Factories by Normax can enable better public health and improved healthcare for people, for example, with mRNA vaccines for infectious diseases such as:

- COVID and Long COVID
- Tuberculosis (TB)
- HIV/AIDS
- Epstein-Barr virus (EBV) which is associated with Multiple sclerosis (MS)
- The next unknown, but inevitable, "Disease-X"

Normax cost to produce mRNA vaccines for infectious disease at large scale is about \$2.00 per dose. Normax plans to price large scale advance purchase agreements for mRNA vaccines for infectious disease at about \$4.00 per dose. This represents a healthy 100% potential profit margin for Normax Investors, but Normax mRNA vaccines can be significantly more cost-effective than other mRNA vaccines which, for example, for COVID are expected to become priced at \$100.00 per dose, or more.

Additional social and economic benefits of Normax include leveraging of Foreign Direct Investment (FDI) with unique financial products for employment (jobs) growth via Domestic and International markets:

- Pharmaceutical industry *jobs*
- Biotech industry *jobs*
- Healthcare services *jobs*
- Export Industry *jobs*
- Commercial property development *jobs*

mRNA vaccine R&D by Normax enables:

- Competitive projected financial performance on debt & equity for investors
- Leveraging Foreign Direct Investment (FDI)
- International Pharmaceutical industry job growth

Vax Factory by Normax enables:

- Affordable domestic mRNA Vaccine Manufacturing Infrastructure
- mRNA vaccine innovation for infectious disease like COVID, TB, HIV, EBV
- International export growth; mRNA Vaccines and Vax Factory by Normax

Normax is committed to support [GOAL 2050](#) to end transmission of TB and HIV by 2050.

Normax is committed to a future with [NO PANDEMICS](#).